GlassScriptPhysician profile
Jill Rice
NPI 1093823361
$4,479.65
in general payments reported to CMS, 2019-2025
19 companies · $1,233 in 2025
The $1,233 reported for 2025 was more than what 84% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $773 · 2022: $1,367 · 2023: $514 · 2024: $592 · 2025: $1,233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,124 · Education: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,123.79 |
| Education | $215.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $1,061.06 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $867.26 | 2025 | Austedo Xr |
| Abbvie INC. | $733.22 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $396.78 | 2021-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $281.43 | 2022-2024 | Caplyta |
| Axsome Therapeutics, INC. | $231.70 | 2023-2024 | Auvelity |
| Neurocrine Biosciences, INC. | $187.80 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $162.31 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $149.51 | 2025 | Nuplazid |
| Biohaven Pharmaceuticals, INC. | $122.58 | 2021 | |
| Eisai INC. | $50.51 | 2021 | |
| Amgen INC. | $47.63 | 2021-2022 | |
| Pfizer INC. | $44.26 | 2023-2024 | |
| Redhill Biopharma INC. | $41.34 | 2021 | |
| Avanir Pharmaceuticals, INC. | $30.88 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $20.93 | 2021 | |
| Alkermes, INC. | $17.31 | 2021 | |
| Currax Pharmaceuticals LLC | $17.20 | 2021 | |
| Allergan, INC. | $15.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Rice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.